Cancer Stem Cell News Volume 14.00 | Jan 15 2025

    0
    25







    2025-01-15 | CSCN 14.00


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 14.00 – 15 January, 2025
    TOP STORY

    AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel via CD44 m6A Modification in Castration Resistant Prostate Cancer

    The authors demonstrated that AGD1, derived from prostate CSCs, enhanced the stemness of prostate cancer cells and reduced the therapeutic effect of docetaxel in castration-resistant prostate cancer.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article
    PUBLICATIONSListed by the impact factor of the journal

    Single-Cell Transcriptomics Reveals Intratumor Heterogeneity and the Potential Roles of Cancer Stem Cells and myCAFs in Colorectal Cancer Liver Metastasis and Recurrence

    Investigators identified a cancer cell subpopulation termed stem/transient amplifying-like cells, which expressed genes associated with stem cell-like characteristics and metastatic potential.
    [Cancer Letters]

    Abstract

    Nicotine Enhances the Stemness and Tumorigenicity in Intestinal Stem Cells via Hippo-YAP/TAZ and Notch Signal Pathway

    Researchers identified a nicotine-triggered pathway regulating the stemness and tumorigenicity of intestinal stem cells and suggested the use of dibenzazepine as a potential therapeutic strategy for treating intestinal tumors.
    [eLife]

    Full Article

    FSD1 Inhibits Glioblastoma Diffuse Infiltration through Restriction of HDAC6-Mediated Microtubule Deacetylation

    Investigators increased expression of fibronectin type III and SPRY domain-containing 1 (FSD1) or interference with FSD1 phosphorylation reduces microtubule deacetylation, suppresses invasion of glioblastoma (GBM) stem cells, and ultimately mitigates tumor infiltration in orthotopic GBM xenografts.
    [Science China Life Sciences]

    Abstract

    LncRNA FGD5-AS1 Facilitates Hepatocellular Carcinoma Cell Stemness by Enhancing PKD1 mRNA Stability through Binding With MSI2

    Both musashi 2 (MSI2) and protein kinase D1 (PKD1) ameliorated short hairpin-long noncoding RNA FGD5 antisense RNA 1’s inhibition of hepatocellular carcinoma cell viability, proliferation, and stemness.
    [Molecular Carcinogenesis]

    Abstract

    Raddeanin A (RA) Inhibited EMT and Stemness in Glioblastoma via downregulating Skp2

    Scientists elucidated Raddeanin A’s significant antitumor efficacy against glioblastoma in vitro and in vivo by targeting pathways linked to stemness and epithelial-mesenchymal transition, chiefly via the downregulation of S phase kinase-associated protein 2 (Skp2).
    [Journal of Cancer]

    Full Article

    Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD-L1 Pathways

    Researchers investigated how arecoline-induced extracellular vesicle secretion suppresses PAX1 protein production through DNA hypermethylation and examined whether PAX1 downregulation enhances cancer stemness and immunosuppression in the tumor microenvironment.
    [Oral Diseases]

    Abstract

    GPLD1+ Cancer Stem Cells Contribute to Chemotherapy Resistance and Tumor Relapse in Intestinal Cancer

    Scientists suggested that targeting of glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) in colorectal cancer might contribute to a new therapeutic strategy that was based on suppression of Wnt signaling and epithelial-mesenchymal transition-related cancer progression driven by CSCs.
    [Journal of Biochemistry]

    Full Article

    MRPL24 Drives Breast Cancer Metastasis and Stemness by Targeting C-MYC, BRD4, and STAT3

    Investigators explored the clinicopathological significance of MRPL24 in human cancers, with a particular focus on breast cancer.
    [3 Biotech]

    Abstract
    REVIEWS

    Insights Into the Role of Bmi-1 Deregulation in Promoting Stemness and Therapy Resistance in Glioblastoma: A Narrative Review

    B-cell-specific Moloney murine leukemia virus insertion site-1 (Bmi-1) regulates self-renewal, proliferation, and differentiation of glioblastoma cells, promoting stemness and therapy resistance. The authors discuss the importance of targeting Bmi-1 which could be a promising therapeutic target for glioblastoma treatment.
    [Cancer Medicine]

    Full Article
    INDUSTRY AND POLICY NEWS

    Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

    Eterna Therapeutics announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system’s response to recognize and attack ovarian cancer cells.
    [Eterna Therapeutics]

    Press Release
    FEATURED EVENT

    Molecules, Mechanisms, and Medicinal Advances in the Mucociliary System

    February 16-21, 2025
    Pomona, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Fellow – Overcoming Pan-Chemoresistance in Cancer Stem Cells

    Anglia Ruskin University – Cambridge, England, United Kingdom

    Faculty – Stem Cell and Gene Therapy

    University of California San Francisco – San Francisco, California, United States

    Postdoctoral Scientist – HPV-Related Head and Neck Cancer

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Tenure-Track Junior PI – Cancer Immunity and Immunotherapy Research

    IFOM ETS – The AIRC Institute of Molecular Oncology – Milan, Italy

    Postdoctoral Scientist – Cancer Biology

    The University of Pennsylvania – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2